Neuropathic pain in patients with sickle cell disease.
Neuropathic pain in patients with sickle cell disease.
复制标题
DOI：
10.1002/pbc.24838
复制
发表时间：
2014-03
影响因子：
3.2
通讯作者：
Panepinto, Julie A.
中科院分区：
文献类型：
--
作者：
Brandow, Amanda M.;Farley, Rebecca A.;Panepinto, Julie A.
尽管提示镰状细胞病（SCD）疼痛的神经性成分，但SCD患者神经性疼痛的系统评估数据很少。神经性疼痛定义为主要由外周或中枢神经系统功能障碍引起的疼痛。在一项横断面研究中，我们使用painDETECT问卷（一页经验证的神经性疼痛筛查工具）来确定SCD患者是否存在神经性疼痛，并评估神经性疼痛、年龄和性别之间的关系。我们假设20%的SCD患者会经历神经性疼痛，并且神经性疼痛与年龄较大和女性相关。完成的painDETECT问卷得出的总分为0-38分（≥19=明确的神经性疼痛，13-18=可能的神经性疼痛，≤12=无神经性疼痛）。评分≥13被指定为具有神经性疼痛的证据。共有56名患者参与。中位年龄为20.3岁，77%为女性。我们发现37%的患者有神经性疼痛的证据。年龄与总评分呈正相关[r=0.43; p=0.001]，表明老年患者经历更多的神经性疼痛。女性的平均总分较高[13 vs 8.4; p=0.04]。显著更多的神经性疼痛患者服用了羟基脲[90% vs 59%; p=0.015]。尽管37%的患者经历神经性疼痛，但只有5%的患者服用神经性疼痛药物。SCD中存在神经病理性疼痛。有效的筛选工具可以识别出从现有和未来的神经性疼痛治疗中受益的患者，并可以确定这些治疗的影响。
Despite the suggestion of a neuropathic component to sickle cell disease (SCD) pain, there are minimal data on the systematic assessment of neuropathic pain in patients with SCD. Neuropathic pain is defined as pain primarily initiated by dysfunction of the peripheral or central nervous system. In a cross-sectional study, we used the painDETECT questionnaire, a one-page validated neuropathic pain screening tool, to determine the presence of neuropathic pain in patients with SCD and to evaluate the relationship between neuropathic pain, age, and gender. We hypothesized that 20% of patients with SCD will experience neuropathic pain and that neuropathic pain will be associated with older age and female gender. The completed painDETECT questionnaire yields a total score between 0–38 (≥19=definite neuropathic pain, 13–18=probable neuropathic pain, ≤12=no neuropathic pain). Scores ≥13 were designated as having evidence of neuropathic pain. A total of 56 patients participated. Median age was 20.3 years and 77% were female. We found 37% of patients had evidence of neuropathic pain. Age was positively correlated with total score [r=0.43; p=0.001] suggesting older patients experience more neuropathic pain. Females had higher mean total scores [13 vs 8.4; p=0.04]. Significantly more patients with neuropathic pain were taking hydroxyurea [90% vs 59%; p=0.015]. Despite 37% of patients experiencing neuropathic pain, only 5% were taking a neuropathic pain drug. Neuropathic pain exists in SCD. Valid screening tools can identify patients that would benefit from existing and future neuropathic pain therapies and could determine the impact of these therapies.
登录
查看更多内容
影响因子：
7.4
作者：
Sethna, Navil F.;Meier, Petra M.;Berde, Charles B.
通讯作者：
Berde, Charles B.
DOI：
10.2174/1874325001307010099
发表时间：
2013-01-01
期刊：
The open orthopaedics journal
影响因子：
--
作者：
Sonohata, Motoki;Tsuruta, Toshiyuki;Mawatari, Masaaki
通讯作者：
Mawatari, Masaaki
影响因子：
158.5
作者：
PLATT, OS;BRAMBILLA, DJ;KLUG, PP
通讯作者：
KLUG, PP
影响因子：
7.4
作者：
Baron, Ralf;Toelle, Thomas R.;Freynhagen, Rainer
通讯作者：
Freynhagen, Rainer
影响因子：
12.8
作者：
Brandow, Amanda M.;Stucky, Cheryl L.;Panepinto, Julie A.
通讯作者：
Panepinto, Julie A.